For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies…
Products
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards…
5 formulation changes you can evaluate with Dynamic Light Scattering to increase your biologics candidates’ success
Biologics researchers are deeply concerned with formulation. Formulation typically refers to the final development of…
NanoTemper’s Monolith wins top global design award: Red Dot Award
NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal…
NanoTemper enters protein production market with Andromeda, helping Biopharma and CROs to increase efficiency of expression screening for membrane proteins
SOUTH SAN FRANCISCO, Calif. June 24, 2021 — NanoTemper Technologies, well-known for creating biophysical tools…
5 experiments in biologics that can be improved with dynamic light scattering
Biologics, which are drugs and treatments derived from natural products, undergo a long development process…
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD)…
NanoTemper’s Monolith wins top global design award: iF DESIGN AWARD 2021
NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly…
Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make…